Search Results

SIFI, a leading ophthalmic company, announced today the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers.

Kinaxis® Inc., the leading supply chain management platform, was selected by F.I.S. - Fabbrica Italiana Sintetici S.p.A. to enable concurrent planning in its supply chain.

SIFI announced that it has partnered with Avanzanite Bioscience, a Dutch specialty pharmaceutical company, to exclusively commercialize and distribute AKANTIOR® in 26 Countries within the European Economic Area and Switzerland.

JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 – BLAU3) today announced that Similis Bio (“Similis”), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacêutica (“Blau”).

AffaMed Technologies, a joint venture established between AffaMed Therapeutics and SIFI S.p.A., announced it has entered into a licensing agreement with SIFI under which AffaMed has obtained the exclusive rights to manufacture, develop and commercialize EVOLUX®, a novel extended monofocal intraocular lens, in Greater China.

SIFI, BeiGene and Novo Holdings shared promising updates on their proposed treatments for acanthamoeba keratitis, relapsed or refractory CCL and myasthenia gravis.

SIFI S.p.A reported the presentation of positive results from the positive Phase 3 Study [NCT03274895] of AKANTIOR®, an investigational anti-amoebic polymer, an orphan drug, for the treatment of acanthamoeba keratitis.

Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A.

SIFI S.p.A., a leading international ophthalmic company headquartered in Italy, announced that it received favorable and supportive feedback from the United States Food and Drug Administration through a ‘Type B’ meeting held in early May regarding its potential regulatory application of AKANTIOR® for the treatment of acanthamoeba keratitis.